In patients with cirrhosis, those with IFNL4 CC genotype were significantly more likely to achieve SVR (16‐week arm, P value = 0.0015; OR = 5.50; CC SVR rate, 76% [26 of 34]; non‐CC SVR rate, 37% [13 of 35]; 24‐week arm, P value = 0.009; OR = 11.38; CC SVR rate, 96% [30 of 31]; non‐CC SVR rate, 73% [29 of 40]). This evidence concerns the gene IFNL4 and Cirrhosis.